Argent Biopharma Limited has released a press release.
Operations Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- Appointment of UK Corporate Advisor and Company Update
- TGA advertising Infringement Notice
- US$550,000 Convertible Note Facility Funding
- Interim Results - CimetrA Dosing Finding Study
- US$750,000 Convertible Note Facility Funding
Later from Argent Biopharma
- Pause in Trading
- Long COVID study Results
- Publication of Peer Reviewed Glioblastoma Research
- US$1,000,000 ArtemiC order delivered to US partner, AMC
- Completion of CimetrA Efficacy Pre-clinical Trial
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma